Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antimicrobial Effectiveness

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Development of Antibiotic Resistance

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers.

Antimicrobial agents and chemotherapy·2026

Same author

Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales.

Microbiology spectrum·2026

Same author

Daptomycin Dosing Based on Adjusted Body Weight in Obese Patients versus Actual Body Weight: A Multicentre Cohort Study.

Infection and drug resistance·2026

Same author

Evaluation of large language models for antimicrobial classification: implications for antimicrobial stewardship programs.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025

Same author

Impact of <i>Pseudomonas aeruginosa</i> biofilm exopolysaccharide composition on bacteriophage and bacteriophage-antibiotic combination activity.

Antimicrobial agents and chemotherapy·2025

Same author

Collaboration to harmonize antimicrobial registry measures (CHARM) database analysis of antibiotic prescribing in urgent and non-urgent care: a retrospective study on demographic factors.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens.

Mohammed Al Musawa¹, Callan R Bleick¹, Shelbye R Herbin^2,3

¹Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Pharmacotherapy

|November 27, 2024

Summary

Aztreonam-avibactam (ATM-AVI) offers a new treatment for difficult gram-negative infections. This combination therapy is effective against multidrug-resistant bacteria, including those producing carbapenemases.

Keywords:

Enterobacterales antimicrobial resistance avibactam aztreonam carbapenemase gram‐negative bacteria metallo‐β‐lactamase monobactam

More Related Videos

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Jun 6, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

Area of Science:

Infectious Diseases
Pharmacology
Microbiology

Background:

Antimicrobial resistance (AMR) is a major global health threat, especially carbapenem-resistant Gram-negative infections.
Metallo-β-lactamases (MBLs) are a growing concern, conferring resistance to many antibiotics.
Aztreonam-avibactam (ATM-AVI) is a novel combination therapy developed to address these challenges.

Purpose of the Study:

To review the chemistry, mechanism of action, and clinical applications of aztreonam-avibactam.
To evaluate the efficacy and safety of ATM-AVI against multidrug-resistant (MDR) Gram-negative pathogens.
To highlight ATM-AVI as a therapeutic option for serious infections.

Main Methods:

Literature review of existing studies on ATM-AVI.
Analysis of in vitro and clinical trial data (e.g., REVISIT, ASSEMBLE).
Examination of pharmacokinetic and pharmacodynamic properties.

Main Results:

ATM-AVI demonstrates broad-spectrum activity against MDR Gram-negative bacteria, including MBL-producers.
Clinical trials show ATM-AVI is safe and effective for complicated intra-abdominal infections, UTIs, and HAP.
Pharmacokinetic data support appropriate dosing, with adjustments for renal impairment.

Conclusions:

Aztreonam-avibactam is a vital new treatment for infections caused by challenging MDR Gram-negative bacteria.
ATM-AVI offers a much-needed therapeutic advance in combating antimicrobial resistance.
Further research aims to optimize its use and expand clinical applications.